NMS Capital, a private equity investment firm, completed the acquisition of Clinical Trials of Texas, a clinical trial with robust infrastructure and processes. Financial terms were not disclosed. “NMS has evaluated several opportunities within outsourced pharmaceutical services during the last few years and identified clinical research sites as a fast growing and fragmented market where we can implement our buy and build approach to investing in multi-site healthcare services companies. We are continuing our thematic investing approach with the formation of Flourish Research and are excited about our initial partnership with CTT. Expanding the site network, our therapeutic capabilities and continuing to focus on clinical excellence and quality data will increase the strategic importance to our sponsor and CRO partners,” Luis Gonzalez, NMS Partner.